INTRODUCTION: Molecular imaging has been defined as the visualization, characterization and measurement of biological processes at the molecular and cellular level in humans and other living systems. In oncology it enables to visualize (part of) the functional behaviour of tumour cells, in contrast to anatomical imaging that focuses on the size and location of malignant lesions. Available molecular imaging techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET) and optical imaging. In PET, a radiotracer consisting of a positron emitting radionuclide attached to the biologically active molecule of interest is administrated to the patient. Several approaches have been undertaken to use PET for the improvement of personalized cancer care. For example, a variety of radiolabelled ligands have been investigated for intratumoural target identification and radiolabelled drugs have been developed for direct visualization of the biodistibution in vivo, including intratumoural therapy uptake. First indications of the clinical value of PET for target identification and response prediction in oncology have been reported. This new imaging approach is rapidly developing, but uniformity of scanning processes, standardized methods for outcome evaluation and implementation in daily clinical practice are still in progress. In this review we discuss the available literature on molecular imaging with PET for personalized targeted treatment strategies. CONCLUSION: Molecular imaging with radiolabelled targeted anticancer drugs has great potential for the improvement of personalized cancer care. The non-invasive quantification of drug accumulation in tumours and normal tissues provides understanding of the biodistribution in relation to therapeutic and toxic effects.
INTRODUCTION: Molecular imaging has been defined as the visualization, characterization and measurement of biological processes at the molecular and cellular level in humans and other living systems. In oncology it enables to visualize (part of) the functional behaviour of tumour cells, in contrast to anatomical imaging that focuses on the size and location of malignant lesions. Available molecular imaging techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET) and optical imaging. In PET, a radiotracer consisting of a positron emitting radionuclide attached to the biologically active molecule of interest is administrated to the patient. Several approaches have been undertaken to use PET for the improvement of personalized cancer care. For example, a variety of radiolabelled ligands have been investigated for intratumoural target identification and radiolabelled drugs have been developed for direct visualization of the biodistibution in vivo, including intratumoural therapy uptake. First indications of the clinical value of PET for target identification and response prediction in oncology have been reported. This new imaging approach is rapidly developing, but uniformity of scanning processes, standardized methods for outcome evaluation and implementation in daily clinical practice are still in progress. In this review we discuss the available literature on molecular imaging with PET for personalized targeted treatment strategies. CONCLUSION: Molecular imaging with radiolabelled targeted anticancer drugs has great potential for the improvement of personalized cancer care. The non-invasive quantification of drug accumulation in tumours and normal tissues provides understanding of the biodistribution in relation to therapeutic and toxic effects.
Authors: Arne R M van der Bilt; Anton G T Terwisscha van Scheltinga; Hetty Timmer-Bosscha; Carolien P Schröder; Linda Pot; Jos G W Kosterink; Ate G J van der Zee; Marjolijn N Lub-de Hooge; Steven de Jong; Elisabeth G E de Vries; Anna K L Reyners Journal: Clin Cancer Res Date: 2012-09-26 Impact factor: 12.531
Authors: C Liedtke; K Broglio; S Moulder; L Hsu; S-W Kau; W F Symmans; C Albarracin; F Meric-Bernstam; W Woodward; R L Theriault; L Kiesel; G N Hortobagyi; L Pusztai; A M Gonzalez-Angulo Journal: Ann Oncol Date: 2009-07-12 Impact factor: 32.976
Authors: Hugo J W L Aerts; Ludwig Dubois; Lars Perk; Peter Vermaelen; Guus A M S van Dongen; Bradly G Wouters; Philippe Lambin Journal: J Nucl Med Date: 2008-12-17 Impact factor: 10.057
Authors: Idris Bahce; Egbert F Smit; Mark Lubberink; Astrid A M van der Veldt; Maqsood Yaqub; Albert D Windhorst; Robert C Schuit; Erik Thunnissen; Daniëlle A M Heideman; Pieter E Postmus; Adriaan A Lammertsma; N Harry Hendrikse Journal: Clin Cancer Res Date: 2012-11-07 Impact factor: 12.531
Authors: Wojciech G Lesniak; Chengyan Chu; Anna Jablonska; Yong Du; Martin G Pomper; Piotr Walczak; Miroslaw Janowski Journal: J Nucl Med Date: 2018-10-12 Impact factor: 10.057
Authors: Idris Bahce; Maqsood Yaqub; Hanane Errami; Robert C Schuit; Patrick Schober; Erik Thunnissen; Albert D Windhorst; Adriaan A Lammertsma; Egbert F Smit; N Harry Hendrikse Journal: EJNMMI Res Date: 2016-02-09 Impact factor: 3.138
Authors: Stefan T G Bruijnen; Durga M S H Chandrupatla; Leonardo Giovanonni; Dario Neri; Danielle J Vugts; Marc C Huisman; Otto S Hoekstra; René J P Musters; Adriaan A Lammertsma; Guus A M S van Dongen; Gerrit Jansen; Carla F M Molthoff; Conny J van der Laken Journal: Mol Pharm Date: 2018-12-24 Impact factor: 4.939
Authors: Lemonitsa H Mammatas; Clasina M Venema; Carolina P Schröder; Henrica C W de Vet; Michel van Kruchten; Andor W J M Glaudemans; Maqsood M Yaqub; Henk M W Verheul; Epie Boven; Bert van der Vegt; Erik F J de Vries; Elisabeth G E de Vries; Otto S Hoekstra; Geke A P Hospers; C Willemien Menke-van der Houven van Oordt Journal: EJNMMI Res Date: 2020-04-19 Impact factor: 3.138
Authors: C Willemien Menke-van der Houven van Oordt; Carlos Gomez-Roca; Carla van Herpen; Andrew L Coveler; Devalingam Mahalingam; Henk M W Verheul; Winette T A van der Graaf; Randolph Christen; Dominik Rüttinger; Stefan Weigand; Michael A Cannarile; Florian Heil; Michael Brewster; Antje-Christine Walz; Tapan K Nayak; Ernesto Guarin; Valerie Meresse; Christophe Le Tourneau Journal: Oncotarget Date: 2016-11-29
Authors: Mariette Labots; Johannes C Van der Mijn; Henk Dekker; Rita Ruijter; Thang V Pham; Hans J Van der Vliet; Jacobus J M Van der Hoeven; Gerrit A Meijer; Henk M W Verheul Journal: Oncologist Date: 2018-07-17